Defining the galaxy of gene expression in breast cancer
Open Access
- 1 August 2002
- journal article
- editorial
- Published by Springer Nature in Breast Cancer Research
- Vol. 4 (4) , 141-144
- https://doi.org/10.1186/bcr438
Abstract
Recent reports detailing the expression profiles of primary breast cancer have pointed to the utility of this approach in defining subclasses with distinct molecular configurations and clinical behaviour. Some of the subclasses can be predicted by current molecular tests: estrogen receptor status, p53 staining, and HER-2 overexpression. Others, however, are novel subgroups and may represent distinct cellular types. The results from two recent studies suggest common principles of classification by expression profiling. These principles are examined and the impact of these results on understanding the biology and the clinical behaviour of breast tumors is explored.Keywords
This publication has 6 references indexed in Scilit:
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized TrialJournal of Clinical Oncology, 2001
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.2001
- Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapyNature Medicine, 1995
- Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.Journal of Clinical Oncology, 1990